BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 1/29

BIOMEDICA free soluble RANKL ELISA - References/Publications

free sRANKL High Sensitivity ELISA REFERENCES published after 2015, using assay #BI-20462

1. Substrate Microarchitecture Shapes the Paracrine Crosstalk of Stem Cells with

Endothelial Cells and Osteoblasts

Francisco Martín-Saavedra, Lara Crespo, Clara Escudero-Duch, Laura Saldaña,

Enrique Gómez-Barrena, and Nuria Vilaboa

Sci Rep. 2017; 7: 15182.

PMCID: PMC5680323

2. Paracrine interactions between mesenchymal stem cells and macrophages are

regulated by 1,25-dihydroxyvitamin D3

Laura Saldaña, Gema Vallés, Fátima Bensiamar, Francisco José Mancebo,

Eduardo García-Rey, and Nuria Vilaboa

Sci Rep. 2017; 7: 14618.

PMCID: PMC5668416

3. Aberrant regulation of RANKL/OPG in women at high risk of developing breast

cancer

Stefan Kiechl, Daniel Schramek, Martin Widschwendter, Evangelia-Ourania

Fourkala, Alexey Zaikin, Allison Jones, Bernadette Jaeger, Brigitte Rack,

Wolfgang Janni, Christoph Scholz, Johann Willeit, Siegfried Weger, Agnes Mayr,

Andrew Teschendorff, Adam Rosenthal, Lindsay Fraser, Susan Philpott, Louis

Dubeau, Mohammed Keshtgar, Rebecca Roylance, Ian J. Jacobs, Usha Menon,

Georg Schett, Josef M. Penninger

Oncotarget, 2017, 3811-3825.

PMID: 28002811

4. Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant

patients

Uwe Lange, Katharina Classen, Ulf Müller-Ladner, Manfred Richter

Clinical Transplantation, 2017.

PMID: 28940569

5. Combined bioavailable isoflavones and probiotics improve bone status and

estrogen metabolism in postmenopausal osteopenic women: a randomized

controlled trial

Max Norman Tandrup Lambert, Catrine Bundgaard Thybo, Simon Lykkeboe, Lars

Melholt Rasmussen, Xavier Frette, Lars Porskjær Christensen, Per Bendix

Jeppesen

The American Journal of Clinical Nutrition, 2017, 909-920.

PMID: 28768651

6. Association of Circulating Osteoprotegerin (OPG) and RANKL with Intracranial

Arterial Calcification in Hypertensive Patients.

Cheng Y., Wang Y. , Guo Q. , Zhu D. , Li Y.

Journal of Hypertension, 2017.

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 2/29

7. Effects of short-term dry immersion on bone remodeling markers, insulin and

adipokines

Marie-Thérèse Linossier , Liubov E. Amirova, Mireille Thomas, Myriam Normand,

Marie-Pierre Bareille, Guillemette Gauquelin-Koch, Arnaud Beck, Marie-Claude

Costes-Salon, Christine Bonneau, Claude Gharib, Marc-Antoine Custaud,

Laurence Vico

PLOS One, 2017.

PMID: 28806419

8. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing

Ewa Śliwicka, Tomasz Cisoń, Zbigniew Kasprzak, Alicja Nowak, and Łucja

Pilaczyńska-Szcześniak

PLoS One. 2017; 12(7): e0181259.

PMCID: PMC5521782

9. Methotrexate and low-dose prednisolone downregulate osteoclast function by

decreasing receptor activator of nuclear factor-κβ expression in monocytes from

patients with early rheumatoid arthritis

Inês Pedro Perpétuo, Joana Caetano-Lopes, Ana Maria Rodrigues, Raquel

Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João

Eurico Fonseca

RMD Open. 2017; 3(1): e000365.

PMCID: PMC5604603

10. Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype:

Results from the EPIC cohort

Danja Sarink, Helena Schock, Theron Johnson, Kim Overvad, Marianne Holm,

Anne Tjønneland, Marie-Christine Boutron-Ruault, Mathilde His, Marina Kvaskoff,

Heiner Boeing, Pagona Lagiou, Eleni-Maria Papatesta, Antonia Trichopoulou,

Domenico Palli, Valeria Pala, Amalia Mattiello, Rosario Tumino, Carlotta

Sacerdote, H.B(as) Bueno-de-Mesquita, Carla H van Gils, Petra H Peeters,

Elisabete Weiderpass, Antonio Agudo, Maria-José Sánchez, Maria-Dolores

Chirlaque, Eva Ardanaz, Pilar Amiano, Kay Tee Khaw, Ruth Travis, Laure Dossus,

Mark Gunter, Sabina Rinaldi, Melissa Merritt,16 Elio Riboli,16 Rudolf Kaaks,1 and

Renée T. Fortner

Cancer Prev Res (Phila). 2017 Sep; 10(9): 525–534.

PMCID: PMC5603271

11. Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral

Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional

Observational Study

Barbara Hauser, Sizheng Zhao, Micaela R. Visconti, Philip L. Riches, William D.

Fraser, Isabelle Piec, Nicola J. Goodson, and Stuart H. Ralston

Calcif Tissue Int. 2017; 101(4): 375–383.

PMCID: PMC5587630

12. Changes in RANKL during the first two years after cART initiation in HIV-infected

cART naïve adults

Inger Hee Mathiesen, Mohammad Salem, Jan Gerstoft, Julie Christine Gaardbo,

Niels Obel, Court Pedersen, Henrik Ullum, Susanne Dam Nielsen, and Ann-Brit Eg

Hansen

BMC Infect Dis. 2017; 17: 262.

PMCID: PMC5387326

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 3/29

13. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for

Charcot arthropathy development

Bożena Bruhn-Olszewska, Anna Korzon-Burakowska, Grzegorz Węgrzyn, and

Joanna Jakóbkiewicz-Banecka

Sci Rep. 2017; 7: 501.

PMCID: PMC5428699

14. Markers of bone metabolism during 14 days of bed rest in young and older men

J. Buehlmeier, P. Frings-Meuthen, N. Mohorko, P. Lau, S. Mazzucco, J.L. Ferretti,

G. Biolo, R. Pisot, B. Simunic, and J. Rittweger

J Musculoskelet Neuronal Interact. 2017 Mar; 17(1): 399–408.

PMCID: PMC538376

15. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in

Rheumatoid Arthritis

Inês P. Perpétuo, Joana Caetano-Lopes, Ana Maria Rodrigues, Raquel

Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João E.

Fonseca

Biomed Res Int. 2017; 2017: 2690402.

PMCID: PMC5327780

16. Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in

Circulating Osteoclast Precursors

Inês P. Perpétuo, Joana Caetano-Lopes, Elsa Vieira-Sousa, Raquel Campanilho-

Marques, Cristina Ponte, Nikita Khmelinskii, Helena Canhão, Mari Ainola, and

João E. Fonseca

Front Med (Lausanne). 2017; 4: 5.

PMCID: PMC5269449

17. NOTCH1 Mutations in Aortic Stenosis: Association with

Osteoprotegerin/RANK/RANKL

Olga Irtyuga, Anna Malashicheva, Ekaterina Zhiduleva, Olga Freylikhman, Oxana

Rotar, Magnus Bäck, Svetlana Tarnovskaya, Anna Kostareva, and Olga Moiseeva

Biomed Res Int. 2017; 2017: 6917907.

PMCID: PMC5299165

18. Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological

Progression in Tightly Controlled Rheumatoid Arthritis

Carmen Gómez-Vaquero, Irene Martín, Estibaliz Loza, Loreto Carmona, José

Ivorra, José Antonio Narváez, Javier Hernández-Gañán, Pedro Alía, and Javier

Narváez

PLoS One. 2016; 11(12): e0166691.

PMCID: PMC5135438

19. HAJDU CHENEY SYNDROME; REPORT OF A NOVEL NOTCH2 MUTATION AND

TREATMENT WITH DENOSUMAB

Adami Giovanni, Rossini Maurizio, Gatti Davide, Orsolini Giovanni, Idolazzi Luca,

Viapiana Ombretta, Scarpa Aldo, and Canalis Ernesto

Bone. 2016 Nov; 92: 150–156.

PMCID: PMC5056853

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 4/29

20. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in

Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease

Ludmila Ugay, Evgenia Kochetkova, Vera Nevzorova, and Yuliya Maistrovskaia

Chin Med J (Engl). 2016 Jul 20; 129(14): 1696–1703.

PMCID: PMC4960959

21. THU0477 Effect of Recent Spinal Cord Injury on the OPG/RANKL System and Its

Relationship with Bone Loss and Antiosteoporotic Response To Denosumab

Therapy. Preliminary Results

L. Gifre, J. Vidal, S. Ruiz-Gaspà, E. Portell, A. Monegal, A. Muxi, N. Guañabens, P.

Peris

Annals of the Rheumatic Diseases, 06.2016.

PMID: 28580511

22. THU0476 Efficacy of Denosumab for The Treatment of Osteoporosis in Japanese

Patients with Rheumatoid Arthritis

K. Oh, O. Namiki, Y. Toyoshima, K. Inagaki, K. Kanbe, J. Chiba

Annals of the Rheumatic Diseases, 06.2016.

PMID: 26585988

23. Path Analysis Identifies Receptor Activator of Nuclear Factor-B Ligand,

Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone

Erosion Relationship in Gout

Ashika Chhana, Opetaia Aati, Gregory D. Gamble, Karen E. Callon, Anthony J.

Doyle, Mark Roger, Fiona M. McQueen, Anne Horne, Ian R. Reid, Jillian Cornish,

and Nicola Dalbeth

J Rheumatol, Feb 2016; 43: 445 - 449.

24. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid

arthritis

Sara Remuzgo-Martínez, Fernanda Genre, Raquel López-Mejías, Begoña Ubilla,

Verónica Mijares, Trinitario Pina, Alfonso Corrales, Ricardo Blanco, Javier Martín,

Javier Llorca, and Miguel A. González-Gaya

Sci Rep. 2016; 6: 29713.

PMCID: PMC4940734

25. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal

study

Helena Schock, Anne Zeleniuch-Jacquotte, Eva Lundin, Kjell Grankvist, Hans-Åke

Lakso, Annika Idahl, Matti Lehtinen, Heljä-Marja Surcel, and Renée T. Fortner

BMC Pregnancy Childbirth. 2016; 16: 146.

PMCID: PMC4932669

26. Toward improved phosphorus efficiency in monogastrics—interplay of serum,

minerals, bone, and immune system after divergent dietary phosphorus supply in

swine

Michael Oster, Franziska Just, Kirsten Büsing, Petra Wolf, Christian Polley, Brigitte

Vollmar, Eduard Muráni, Siriluck Ponsuksili, and Klaus Wimmers

Am J Physiol Regul Integr Comp Physiol. 2016 May 15; 310(10): R917–R925.

PMCID: PMC4896080

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 5/29

27. Denosumab versus zoledronic acid in patients previously treated with zoledronic

acid.

Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I,

Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.

Osteoporos Int. 2015 Oct;26(10):2521-7.

PMID: 25990355

28. Notch Signaling Induces Root Resorption via RANKL and IL-6 from hPDL Cells

J. Kikuta, M. Yamaguchi, M. Shimizu, T. Yoshino, and K. Kasai

Journal of Dental Research, Jan 2015; 94: 140-147.

PMID: 25376720

free sRANKL ELISA REFERENCES published before 2015, using assays #BI-20422H, #BI-20452

29. Clinical, instrumental, serological and histological findings suggest that hemophilia

B may be less severe than hemophilia A

Daniela Melchiorre, Silvia Linari, Mirko Manetti, Eloisa Romano, Francesco Sofi,

Marco Matucci-Cerinic, Christian Carulli, Massimo Innocenti, Lidia Ibba-Manneschi,

and Giancarlo Castaman

Haematologica, Feb 2016; 101: 219 - 225.

PMCID: PMC4938330

30. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in

Ankylosing Spondylitis

Inês P. Perpétuo, Rita Raposeiro, Joana Caetano-Lopes, Elsa Vieira-Sousa, Raquel

Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João E.

Fonseca

PLoS One. 2015; 10(12): e0144655.

PMCID: PMC4682624

31. Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and

sRANKL Concentrations in Patients with Rheumatoid Arthritis

Katharina Kurz, Manfred Herold, Elisabeth Russe, Werner Klotz, Guenter Weiss,

and Dietmar Fuchs

Dis Markers. 2015; 2015: 276969.

PMCID: PMC4631883

32. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a

cross-sectional, observational study

Eva Kulcsar-Jakab, Zsofia Petho, Zoltan Pap, Edit Kalina, Roza Foldesi, Adam

Balogh, Peter Antal-Szalmas, and Harjit Pal Bhattoa

BMC Musculoskelet Disord. 2015; 16: 227.

PMCID: PMC4551745

33. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone

marrow stromal cells and impairs the resorbing activity of mature osteoclasts

Maria Rita Pitari, Marco Rossi, Nicola Amodio, Cirino Botta, Eugenio Morelli, Cinzia

Federico, Annamaria Gullà, Daniele Caracciolo, Maria Teresa Di Martino,

Mariamena Arbitrio, Antonio Giordano, Pierosandro Tagliaferri, and Pierfrancesco

Tassone

Oncotarget. 2015 Sep 29; 6(29): 27343–27358.

PMCID: PMC4694994

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 6/29

34. Osteoprotegerin is a significant prognostic factor for overall survival in patients

with primary systemic amyloidosis independent of the Mayo staging

E Kastritis, M Gavriatopoulou, M A Dimopoulos, E Eleutherakis-Papaiakovou, N

Kanellias, M Roussou, C Pamboucas, S T Toumanidis, and E Terpos

Blood Cancer J. 2015 Jun; 5(6): e319.

PMCID: PMC4648482

35. Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic

dendritic cells via RANKL secretion

Stéphanie A Demoulin, Joan Somja, Anaëlle Duray, Samuel Guénin, Patrick

Roncarati, Philippe O Delvenne, Michael F Herfs, and Pascale M Hubert

Oncoimmunology. 2015 Jun; 4(6): e1008334.

PMCID: PMC4485731

36. Topographical cues regulate the crosstalk between MSCs and macrophages

Gema Vallés, Fátima Bensiamar, Lara Crespo, Manuel Arruebo, Nuria Vilaboa, and

Laura Saldañaa

Biomaterials. 2015 Jan; 37: 124–133.

PMCID: PMC4245715

37. Denosumab for the prevention of skeletal complications in metastatic castration-

resistant prostate cancer: comparison of skeletal-related events and symptomatic

skeletal events

M. R. Smith, R. E. Coleman, L. Klotz, K. Pittman, P. Milecki, S. Ng, K. N. Chi, A.

Balakumaran, R. Wei, H. Wang, A. Braun, and K. Fizazi

Ann Oncol. 2015 Feb;26(2):368-374.

PMID: 25425475

38. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone

mineral density: changes in bone turnover markers and circulating sclerostin

levels

Eugènia Negredo, Adolfo Diez-Pérez, Anna Bonjoch, Pere Domingo, Núria Pérez-

Álvarez, Mar Gutierrez, Gracia Mateo, Jordi Puig, Patricia Echeverría, Roser Escrig,

and Bonaventura Clotet

J. Antimicrob. Chemother., 2015; 70: 2104-2107

PMID: 25769303

39. Ultrasonographic examination of rheumatoid arthritis patients who are free of

physical synovitis: power Doppler subclinical synovitis is associated with bone

erosion

Shin-ya Kawashiri, Takahisa Suzuki, Yoshikazu Nakashima, Yoshiro Horai,

Akitomo Okada, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Kazuhiko Arima,

Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Kiyoshi Aoyagi, Katsumi

Eguchi, and Atsushi Kawakami

Rheumatology, Mar 2014; 53: 562-569.

PMID: 24319104

40. Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble

tumor necrosis factor receptor use

Mie Jin Lim, Seong Ryul Kwon, Kowoon Joo, Min Jung Son, Shin-Goo Park, and

Won Park

Korean J Intern Med. 2014 Nov; 29(6): 807–813.

PMCID: PMC4219971

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 7/29

41. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis

Kristyna Brabnikova-Maresova, Katerina Jarosova, Karel Pavelka, and Jan J

Stepan

Arthritis Res Ther. 2014; 16(5): 460.

PMCID: PMC4236454

42. Bone mineral status in Egyptian children with classic congenital adrenal

hyperplasia. A single-center study from Upper Egypt

Kotb Abbass Metwalley and Abdel-Rahman Abbdel-Hamed El-Saied

Indian J Endocrinol Metab. 2014 Sep-Oct; 18(5): 700–704.

PMCID: PMC4171895

43. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are

not changed in individuals with high bone mass causing mutations in LRP5

Osteoporos Int. 2014 Oct; 25(10): 2383–2388.

PMCID: PMC4659359

44. Osteoclastogenic Potential of Peripheral Blood Mononuclear Cells in Cleidocranial

Dysplasia

Maria Felicia Faienza, Annamaria Ventura, Laura Piacente, Maria Ciccarelli,

Margherita Gigante, Loreto Gesualdo, Silvia Colucci, Luciano Cavallo, Maria Grano,

and Giacomina Brunetti

Int J Med Sci. 2014; 11(4): 356–364.

PMCID: PMC3936030

45. Relationship between Biochemical Bone Markers and Bone Mineral Density in

Patients with Phenylketonuria under Restricted Diet

Hala M. Koura, Sherif M. Zaki, Nagwa A. Ismail, Emad E. Salama, Dalia H. El

Lebedy, and Laila K. Effat

Iran J Pediatr. 2014 Feb; 24(1): 23–28.

PMCID: PMC4359600

46. Independent relationship of osteoprotegerin concentrations with endothelial

activation and carotid atherosclerosis in patients with severe rheumatoid arthritis.

Patrick H. Dessein, Raquel López-Mejias, Carlos González-Juanatey, Fernanda

Genre, José A. Miranda-Filloy, Javier Llorca, and Miguel A. González-Gay

J Rheumatol, Mar 2014; 41: 429-436.

PMID: 24488413

47. Synovial membrane immunohistology in early-untreated rheumatoid arthritis

reveals high expression of catabolic bone markers that is modulated by

methotrexate

Shankar Revu, Petra Neregård, Erik af Klint, Marina Korotkova, and Anca Irinel

Catrina

Arthritis Res Ther. 2013; 15(6): R205.

PMCID: PMC3978873

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 8/29

48. OPG and sRANKL serum levels and incident hip fracture in postmenopausal

Caucasian women in the Women's Health Initiative Observational Study

Andrea Z. LaCroix, Rebecca D. Jackson, Aaron Aragaki, Charles Kooperberg, Jane

A. Cauley, Zhao Chen, Meryl S. LeBoff, David Duggan, and Jean Wactawski-

Wendeg

Bone. 2013 Oct; 56(2): 10.1016/j.bone.2013.05.018.

PMCID: PMC3832355

49. Juvenile Paget’s Disease In An Iranian Kindred With Vitamin D Deficiency And

Novel Homozygous TNFRSF11B Mutation

Forough Saki, Zohreh Karamizadeh, Shiva Nasirabadi, Steven Mumm, William H.

McAlister, and Michael P. Whyte

J Bone Miner Res. 2013 Jun; 28(6): 1501–1508.

PMID: PMC3663917

50. Osteoprotegerin inhibits bone resorption and prevents tumor development in a

xenogenic model of Ewing's sarcoma by inhibiting RANKL

Gaëlle Picarda, Etienne Matous, Jérôme Amiaud, Céline Charrier, François

Lamoureux, Marie-Françoise Heymann, Franck Tirode, Bruno Pitard, Valérie

Trichet, Dominique Heymann, and Françoise Redini

J Bone Oncol. 2013 Sep; 2(3): 95–104.

PMCID: PMC4723385

51. Human Apolipoprotein E Isoforms differentially affect Bone Mass and Turnover in

vivo

Marco Dieckmann, F. Timo Beil, Brigitte Mueller, Alexander Bartelt, Robert P.

Marshall, Till Koehne, Michael Amling, Wolfgang Ruether, Jackie A. Cooper,6 Steve

E. Humphries, Joachim Herz, and Andreas Niemeier

J Bone Miner Res. 2013 Feb; 28(2): 236–245.

PMCID: PMC3547162

52. Increased vertebral morphometric fracture in patients with postsurgical

hypoparathyroidism despite normal bone mineral density

Maira L Mendonça, Francisco A Pereira, Marcello H Nogueira-Barbosa, Lucas M

Monsignore, Sara R Teixeira, Plauto CA Watanabe, Lea MZ Maciel, and Francisco

JA de Paula

BMC Endocr Disord. 2013; 13: 1.

PMCID: PMC3546901

53. Traditional and Novel Bone Remodeling Markers in Premenopausal and

Postmenopausal Women

Sonsoles Botella, Patricia Restituto, Ignacio Monreal, Inmaculada Colina, Amparo

Calleja, and Nerea Varo

J. Clin. Endocrinol. Metab., Nov 2013; 98: E1740-E1748.

PMID: 24001743

54. Activation of the receptor activator of the nuclear factor-B ligand pathway during

coronary bypass surgery: comparison between on- and off-pump coronary artery

bypass surgery procedures

Antonella Galeone, Giacomina Brunetti, Crescenzia Rotunno, Angela Oranger,

Silvia Colucci, Luigi de Luca Tupputi Schinosa, Alberta Zallone, Maria Grano, and

Domenico Paparella

Eur J Cardiothorac Surg, Aug 2013; 44: e141-e147.

PMID: 23671202

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 9/29

55. An Independent Positive Relationship Between the Serum Total Osteocalcin Level

and Fat-Free Mass in Healthy Premenopausal Women

Jian-min Liu, Hong-yan Zhao, Lin Zhao, Ying Chen, Lian-zhen Zhang, Bei Tao, Li-

hao Sun, Yong-ju Zhao, Wei-qing Wang, Man-yin Xu, Jia-lun Chen, and Guang

Ning

J. Clin. Endocrinol. Metab., May 2013; 98: 2146-2152.

PMID: 23553865

56. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I

degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible

mechanism for specific inhibition of radiological destruction

Inga-Lill Engvall, Björn Svensson, Annelies Boonen, Désirée van der Heijde, Ulf H.

Lerner, Ingiäld Hafström, and on behalf of the BARFOT study group

Rheumatology, Apr 2013; 52: 733-742.

PMID: 23275387

57. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase

deficiency on chronic glucocorticoid treatment

Giacomina Brunetti, Maria Felicia Faienza, Laura Piacente, Annamaria Ventura,

Angela Oranger, Claudia Carbone, Adriana Di Benedetto, Graziana Colaianni,

Margherita Gigante, Giorgio Mori, Loreto Gesualdo, Silvia Colucci, Luciano Cavallo,

and Maria Grano

Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554.

PMID: 23299503

58. Receptor Activator for NF-B Ligand in Acute Myeloid Leukemia: Expression,

Function, and Modulation of NK Cell Immunosurveillance

Benjamin Joachim Schmiedel, Tina Nuebling, Julia Steinbacher, Alexandra

Malinovska, Constantin Maximilian Wende, Miyuki Azuma, Pascal Schneider,

Ludger Grosse-Hovest, and Helmut Rainer Salih

J. Immunol., Jan 2013; 190: 821 - 831.

PMID: 23241893

59. Bone metabolism compensates for the delayed growth in small for gestational age

neonates

Roxane Tenta, Ifigeneia Bourgiezi, Evangelos Aliferis, Magdalini Papadopoulou,

Antonis Gounaris, and Maria Skouroliakou

Organogenesis. 2013 Jan 1; 9(1): 55–59.

PMCID: PMC3674041

60. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and

Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A

Randomized, Head-to-Head Clinical Trial

Athanasios D. Anastasilakis, Stergios A. Polyzos, Athina Gkiomisi, Ilias Bisbinas,

Spyridon Gerou, and Polyzois Makras

J. Clin. Endocrinol. Metab., 2013; 98: 3206-3212.

PMID: 23788684

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 10/29

61. Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with

bisphosphonates alone or in combination with pitavastatin over an 18-month

follow-up after more than 4 years of treatment with bisphosphonates

Masakazu Nagashima, Hiroshi Takahashi, Kenichi Shimane, Yuichi Nagase, and

Koichi Wauke

Arthritis Res Ther. 2012; 14(5): R224.

PMCID: PMC3580535

62. Changes of Serum Soluble Receptor Activator for Nuclear Factor-κB Ligand after

Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts

Kaneko K, Kusunoki N, Hasunuma T, Kawai S.

The Journal of Clinical Endocrinology and Metabolism. 2012;97(10):E1909-E1917.

PMCID: PMC3462941

63. Vertebral fractures in patients with inflammatory bowel disease COMPARED with a

healthy population: a prospective case-control study

Vázquez MA, Lopez E, Montoya MJ, Giner M, Pérez-Temprano R, Pérez-Cano R.

BMC Gastroenterology. 2012;12:47.

PMCID: PMC3438096

64. The relationship between osteoclastogenic and anti-osteoclastogenic pro-

inflammatory cytokines differs in human osteoporotic and osteoarthritic bone

tissues

Zupan J, Komadina R, Marc J.

Journal of Biomedical Science. 2012;19(1):28.

PMCID: PMC3307025

65. Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in

Multiple Myeloma

Clive Henry Buckle, Evy De Leenheer, Michelle Anne Lawson, Kwee Yong, Neil

Rabin, Mark Perry, Karen Vanderkerken, and Peter Ian Croucher

PLoS ONE. 2012;7(8):e41127.

PMCID: PMC3430669

66. Changes of Serum Soluble Receptor Activator for Nuclear Factor-B Ligand after

Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts

Kaichi Kaneko, Natsuko Kusunoki, Tomoko Hasunuma, and Shinichi Kawai

J. Clin. Endocrinol. Metab., Oct 2012; 97: E1909 - E1917.

PMCID: PMC3462941

67. Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell

Histiocytosis

Polyzois Makras, Stergios A. Polyzos, Athanasios D. Anastasilakis, Evangelos

Terpos, George Kanakis, Marian Schini, Athanasios Papatheodorou, and Gregory

A. Kaltsas

J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621.

PMID: 22278426

68. Diets Higher in Dairy Foods and Dietary Protein Support Bone Health during Diet-

and Exercise-Induced Weight Loss in Overweight and Obese Premenopausal

Women

Andrea R. Josse, Stephanie A. Atkinson, Mark A. Tarnopolsky, and Stuart M.

Phillips

J. Clin. Endocrinol. Metab., Jan 2012; 97: 251 - 260.

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 11/29

PMID: 22049177

69. First inducible transgene expression in porcine large animal models

Nikolai Klymiuk, Wolfgang Böcker, Veronika Schönitzer, Andrea Bähr, Tamara

Radic, Thomas Fröhlich, Annegret Wünsch, Barbara Keßler, Mayuko Kurome,

Eleonore Schilling, Nadja Herbach, Rüdiger Wanke, Hiroshi Nagashima, Wolf

Mutschler, Georg J. Arnold, Reinhard Schwinzer, Matthias Schieker, and Eckhard

Wolf

FASEB J, Mar 2012; 26: 1086 - 1099.

PMID: 22138035

70. Evolution of coronary artery calcification in patients with chronic kidney disease

Stages 3 and 4, with and without diabetes

Aristeidis Stavroulopoulos, Christine J. Porter, Kate Pointon, John M. Monaghan,

Simon D. Roe, and Michael J.D. Cassidy

Nephrol. Dial. Transplant., Aug 2011; 26: 2582 - 2589.

PMID: 21224493

71. RANKL Is a Downstream Mediator for Insulin-Induced Osteoblastic Differentiation

of Vascular Smooth Muscle Cells

Ling-Qing Yuan, Jia-Hua Zhu, Hua-Wen Wang, Qiu-Hua Liang, Hui Xie, Xian-Ping

Wu, Hua Zhou, Rong-Rong Cui, Zhi-Feng Sheng, Hou-De Zhou, Xiao Zhu, Guan-

Ying Liu, You-Shuo Liu, and Er-Yuan Liao

PLoS ONE. 2011;6(12):e29037.

PMCID: PMC3240644

72. Correlation of Circulating Omentin-1 with Bone Mineral Density in Multiple

Sclerosis: The Crosstalk between Bone and Adipose Tissue

Majid Assadi, Hooman Salimipour, Samad Akbarzadeh, Reza Nemati, Syed

Mojtaba Jafari, Afshar Bargahi, Zahra Samani, Mohammad Seyedabadi, Zahra

Sanjdideh, and Iraj Nabipour

PLoS ONE. 2011;6(9):e24240.

PMCID: PMC3174149

73. The RANKL/RANK/OPG Signaling Pathway Mediates Medial Arterial Calcification in

Diabetic Charcot Neuroarthropathy

Agbor Ndip, Alfred Williams, Edward B. Jude, Ferdinand Serracino-Inglott, Steve

Richardson, J.V. Smyth, Andrew J.M. Boulton, and M. Yvonne Alexander

Diabetes, Aug 2011; 60: 2187 - 2196.

PMCID: PMC3142088

74. Serum osteoprotegerin levels are related to height loss: The Tromsø Study

Jørgensen L, Hansen J-B, Brox J, Mathiesen E, Vik A, Jacobsen BK.

European Journal of Epidemiology. 2011;26(4):305-312.

PMCID: PMC3088831

75. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with

type 2 diabetes mellitus

Jong Suk Park, Min Ho Cho, Ji Sun Nam, Jeong Seon Yoo, Chul Woo Ahn, Bong

Soo Cha, Kyung Rae Kim, and Hyun Chul Lee

Eur. J. Endocrinol., Jan 2011; 164: 69 - 74.

PMCID: PMC3000683

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 12/29

76. Circulating osteoprotegerin and soluble receptor activator of nuclear factor B

ligand in polycystic ovary syndrome: relationships to insulin resistance and

endothelial dysfunction

Carmen Emanuela Pepene, Ioana Rada Ilie, Ioan Marian, and Ileana Duncea

Eur. J. Endocrinol., Jan 2011; 164: 61 - 68.

PMID: 20974706

77. Dissociation of Osteogenic and Immunological Effects by the Selective

Glucocorticoid Receptor Agonist, Compound A, in Human Bone Marrow Stromal

Cells.

Martina Rauner, Claudia Goettsch, Nicola Stein, Sylvia Thiele, Martin Bornhaeuser,

Karolien De Bosscher, Guy Haegeman, Jan Tuckermann, and Lorenz C. Hofbauer

Endocrinology, Jan 2011; 152: 103 - 112.

PMID: 21084452

78. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB

(sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and

osteoprotegerin (OPG) during proximal humerus fracture healing

Alessandra Colombini, Giovanni Lombardi, Emanuela Galliera, Giada Dogliotti,

Pietro Randelli, Alexander Meerssemann, Giuseppe Mineo, Paolo Cabitza, and

Massimiliano Marco Corsi

International Orthopaedics. 2011;35(5):777-782.

PMCID: PMC3080502

79. Circulating osteoprotegerin and soluble receptor activator of nuclear factor B

ligand in polycystic ovary syndrome: relationships to insulin resistance and

endothelial dysfunction.

Carmen Emanuela Pepene, Ioana Rada Ilie, Ioan Marian, and Ileana Duncea

Eur. J. Endocrinol., Jan 2011; 164: 61 - 68.

PMID: 20974706

80. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children

Wasilewska A, Rybi-Szuminska A, Zoch-Zwierz W.

Pediatric Nephrology. 2010;25(10):2067-2075.

PMCID: PMC2923718

81. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict

annual radiological progression over 11 years in rheumatoid arthritis.

Lilian H D van Tuyl, Alexandre E Voskuyl, Maarten Boers, Piet Geusens, Robert B

M Landewé, Ben A C Dijkmans, and Willem F Lems

Ann Rheum Dis, Sep 2010; 69: 1623 - 1628.

PMID: 20525836

82. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-

derived mesenchymal stromal cells into osteoblasts

Hichame Id Boufker, Laurence Lagneaux, Mehdi Najar, Martine Piccart, Ghanem

Ghanem, Jean-Jacques Body, and Fabrice Journé

BMC Cancer. 2010;10:298.

PMCID: PMC3087319

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 13/29

83. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease,

incident CVD and mortality

Wolfgang Lieb, Philimon Gona, Martin G. Larson, Joseph M Massaro, Izabella

Lipinska, John F. Keaney, Jr, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S

Fox, Ramachandran S. Vasan, Emelia J. Benjamin, Christopher J O’Donnell, and

Sekar Kathiresan

Arteriosclerosis, thrombosis, and vascular biology. 2010;30(9):1849-1854.

PMCID: PMC3039214

84. Bone mineral density, bone turnover markers, lean mass, and fat mass in

Egyptian children with congenital adrenal hyperplasia

Soha M. Abd El Dayem, Ghada M. Anwar, Hassan Salama, Ashraf F. Kamel, and

Nahed Emara

Archives of Medical Science : AMS. 2010;6(1):104-110.

PMCID: PMC3278952

85. No significant effect on bone mineral density by high doses of vitamin D3 given to

overweight subjects for one year

Rolf Jorde, Monica Sneve, Peter A Torjesen, Yngve Figenschau, John-Bjarne

Hansen, and Guri Grimnes

Nutrition Journal. 2010;9:1.

PMCID: PMC2818614

86. Genome-Wide Association Meta-Analysis of Cortical Bone Mineral Density Unravels

Allelic Heterogeneity at the RANKL Locus and Potential Pleiotropic Effects on Bone

Lavinia Paternoster, Mattias Lorentzon, Liesbeth Vandenput, Magnus K. Karlsson,

Östen Ljunggren, Andreas Kindmark, Dan Mellstrom, John P. Kemp, Caroline E.

Jarett, Jeff M. P. Holly, Adrian Sayers, Beate St. Pourcain, Nicholas J. Timpson,

Panos Deloukas, George Davey Smith, Susan M. Ring, David M. Evans, Jon H.

Tobias, and Claes Ohlsson

PLoS Genetics. 2010;6(11):e1001217.

PMCID: PMC2987837

87. Circulating mediators of bone remodeling in psoriatic arthritis: implications for

disordered osteoclastogenesis and bone erosion

Nicola Dalbeth, Bregina Pool, Timothy Smith, Karen E Callon, Maria Lobo, William

J Taylor, Peter B Jones, Jillian Cornish, and Fiona M McQueen

Arthritis Research & Therapy. 2010;12(4):R164.

PMCID: PMC2945067

88. Bone Impairment in Phenylketonuria Is Characterized by Circulating Osteoclast

Precursors and Activated T Cell Increase

Ilaria Roato, Francesco Porta, Alessandro Mussa, Lucia D'Amico, Ludovica Fiore,

Davide Garelli, Marco Spada, and Riccardo Ferracini

PLoS ONE. 2010;5(11):e14167.

PMCID: PMC2994752

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 14/29

89. Biomarkers of the Osteoprotegerin Pathway: Clinical Correlates, Subclinical

Disease, Incident Cardiovascular Disease, and Mortality.

Wolfgang Lieb, Philimon Gona, Martin G. Larson, Joseph M. Massaro, Izabella

Lipinska, John F. Keaney, Jr, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S.

Fox, Ramachandran S. Vasan, Emelia J. Benjamin, Christopher J. O'Donnell, and

Sekar Kathiresan

Arterioscler Thromb Vasc Biol, Sep 2010; 30: 1849 - 1854.

PMID: 20448212

90. Persistent increase of osteoprotegerin levels after cortisol normalization in

patients with Cushing's syndrome.

Valentina Camozzi, Francesca Sanguin, Nora Albigier, Carla Scaroni, Franco

Mantero, Martina Zaninotto, Annachiara Frigo, Michele Piccolo, and Giovanni

Luisetto

Eur. J. Endocrinol., Jan 2010; 162: 85 - 90.

PMID: 19793762

91. Biomarkers in early rheumatoid arthritis: longitudinal associations with

inflammation and joint destruction measured by magnetic resonance imaging and

conventional radiographs.

Silje W Syversen, Espen A Haavardsholm, Pernille Bøyesen, Guro L Goll, Cecilie

Okkenhaug, Per Ivar Gaarder, Désirée van der Heijde, and Tore K Kvien

Ann Rheum Dis. 2010 May;69(5):845-50.

PMID: 20233753

92. Alendronate reduces osteoclast precursors in osteoporosis.

P D'Amelio, A Grimaldi, MA Cristofaro, M Ravazzoli, PA Molinatti, GP Pescarmona,

and GC Isaia

Osteoporos Int. 2010 Oct;21(10):1741-50.

PMID: 19949772

93. Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors,

Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after

Viral Hepatitis.

Jorge L. González-Calvin, Jose L. Mundi, Francisco J. Casado-Caballero, Ana C.

Abadia, and Jose J. Martin-Ibañez

J. Clin. Endocrinol. Metab., Dec 2009; 94: 4844 - 4850.

PMID: 19897681

94. ADA-deficient SCID is associated with a specific microenvironment and bone

phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency

Aisha V. Sauer, Emanuela Mrak, Raisa Jofra Hernandez, Elena Zacchi, Francesco

Cavani, Miriam Casiraghi, Eyal Grunebaum, Chaim M. Roifman, Maria C. Cervi,

Alessandro Ambrosi, Filippo Carlucci, Maria Grazia Roncarolo, Anna Villa,

Alessandro Rubinacci, and Alessandro Aiuti

Blood, Oct 2009; 114, 3216-3226.

PMID: 19633200

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 15/29

95. Non-association Between Polymorphisms of the Frizzled Receptor Genes and Bone

Mineral Density in Postmenopausal Korean Women

Jung Gu Kim, Hoon Kim, Byung Chul Jee, Chang Suk Suh, Young Min Choi, and

Shin Yong Moon

Journal of Korean Medical Science. 2009;24(3):443-447.

PMCID: PMC2698190

96. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α

agonist fenofibrate and the PPARγ agonist pioglitazone

Unni Syversen, Astrid K Stunes, Björn I Gustafsson, Karl J Obrant, Lars

Nordsletten, Rolf Berge, Liv Thommesen, and Janne E Reseland

BMC Endocrine Disorders. 2009;9:10.

PMCID: PMC2678137

97. Increased serum OPG in atrophic nonunion shaft fractures

Marchelli D, Piodi LP, Corradini C, Parravicini L, Verdoia C, Ulivieri FM.

Traumatology : Official Journal of the Italian Society of Orthopaedics and

Traumatology. 2009;10(2):55-58.

PMCID: PMC2688591

98. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts

Mizutani K, Sud S, Pienta KJ.

Journal of cellular biochemistry. 2009;106(4):563-569.

PMCID: PMC2776620

99. Bone Turnover and the Osteoprotegerin-RANKL Pathway in Tumor-Induced

Osteomalacia: A Longitudinal Study of Five Cases.

Domenico Rendina, Gianpaolo De Filippo, Libuse Tauchmanova, Luigi Insabato,

Riccardo Muscariello, Fernando Gianfrancesco, Teresa Esposito, Michele Cioffi,

Annamaria Colao, Pasquale Strazzullo, and Giuseppe Mossetti

Calcif Tissue Int, Sep 2009;

PMID: 19763378

100.

A 246-km continuous running race causes significant changes in bone

metabolism.

Katharina Kerschan-Schindl, Markus Thalmann, Gottfried H Sodeck, Katerina

Skenderi, Antonia L Matalas, Stephan Grampp, Christof Ebner, and Peter

Pietschmann

Bone. 2009 Dec;45(6):1079-83.

PMID: 19665602

101.

Chronic antiepileptic monotherapy, bone metabolism, and body composition in

non-institutionalized children.

Markus Rauchenzauner, Andrea Griesmacher, Tobias Tatarczyk, Edda Haberlandt,

Alexander Strasak, Lothar-Bernd Zimmerhackl, Gerda Falkensammer, Gerhard

Luef, and Wolfgang Hogler

Dev Med Child Neurol. 2010 Mar;52(3):283-8.

PMID: 19709134

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 16/29

102.

Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB

ligand: the Tromsø Study.

L Jorgensen, A Vik, N Emaus, J Brox, J-B Hansen, E Mathiesen, and P Vestergaard

Osteoporos Int. 2010 Jun;21(6):931-8.

PMID: 19701599

103.

The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL

in Patients with Paget's Disease of Bone.

S A Polyzos, A D Anastasilakis, Z Efstathiadou, M Kita, I Litsas, A Avramidis, G

Arsos, E Moralidis, S Gerou, V Pavlidou, A Papatheodorou, and E Terpos

Horm Metab Res. 2009 Nov;41(11):846-50.

PMID:19670154

104. Interleukin-17, RANKL, and osteoprotegerin

levels in gingival crevicular fluid from smoking and non-smoking patients with

chronic periodontitis during initial periodontal treatment.

N Buduneli, E Buduneli, and N Kutukculer

J Periodontol, Aug 2009; 80(8): 1274-80.

PMID: 19656027

105.

Osteoclastogenesis in Children with 21-hydroxylase Deficiency on Long Term

Glucocorticoid Therapy: The Role of RANKL/OPG Imbalance.

Giacomina Brunetti, Silvia Colucci, Laura Piacente, Maria Ciccarelli, Lucia Giordani,

Giovanni Carlo Del Vecchio, Massimo D'Amore, Livia Albanese, Luciano Cavallo,

and Maria Grano

J. Clin. Endocrinol. Metab., Jul 2009; 94:2269-2276.

PMID: 19401376

106.

The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients:

Surveillance, Management and Prognostic Implications.

Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E,

Harrington KJ, Polyzos A, Syrigos KN.

Anticancer Res, May 2009; 29: 1651 - 1657.

PMID: 19443381

107.

Serum bone turnover markers may be involved in the metastatic potential of lung

cancer patients.

Eleni M Karapanagiotou, Evangelos Terpos, Kalliopi D Dilana, Christina Alamara,

Ioannis Gkiozos, Aris Polyzos, and Kostas N Syrigos

Med Oncol. 2010 Jun;27(2):332-8.

PMID: 19373566

Relationships between OPG, RANKL, bone metabolism, and bone mineral density

in biliary atresia.

S Honsawek, T Chaiwatanarat, P Vejchapipat, V Chongsrisawat, N Thawornsuk,

and Y Poovorawan

Pediatr Surg Int, Mar 2009; 25(3): 261-7.

PMID: 19184056

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 17/29

108.

Proinflammatory cytokines and receptor activator of nuclear factor kappaB-

ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's

disease.

N Turk, S Cukovic-Cavka, M Korsic, Z Turk, and B Vucelic

Eur J Gastroenterol Hepatol, Feb 2009; 21(2): 159-66.

109.

High osteoprotegerin serum levels in primary biliary cirrhosis are associated with

disease severity but not with the mRNA gene expression in liver tissue.

Nuria Guanabens, Anna Enjuanes, Luisa Alvarez, Pilar Peris, Llorenc Caballeria, M

Jesus Martinez de Osaba, Dacia Cerda, Anna Monegal, Francesca Pons, and Albert

Pares

J Bone Miner Metab. 2009;27(3):347-54.

PMID: 19229472

110.

Effect of Anti-Infective Mechanical Therapy on Clinical Parameters and Cytokine

Levels in Human Peri-Implant Diseases.

Poliana Mendes Duarte, Adriana Cutrim de Mendonca, Maria Beatriz Braz Maximo,

Vanessa Renata Santos, Marta Ferreira Bastos, and Francisco Humberto Nociti

J Periodontol, Feb 2009; 80(2): 234-243.

PMID: 19186963

111.

Dysregulated RANK Ligand/RANK Axis in Hyperhomocysteinemic Subjects: Effect

of Treatment With B-Vitamins.

Marit S. Nenseter, Thor Ueland, Kjetil Retterstøl, Ellen Strøm, Lars Mørkrid, Sverre

Landaas, Leiv Ose, Pål Aukrust, and Kirsten B. Holven

Stroke, Jan 2009; 40: 241 – 247

PMID: 19008470

112.

The HLA-B27 Transgenic Rat, a Model of Spondyloarthritis, Has Decreased Bone

Mineral Density and Increased RANKL to Osteoprotegerin mRNA Ratio.

Martina Rauner, Daniela Stupphann, Martin Haas, Ingrid Fert, Simon Glatigny,

Wolfgang Sipos, Maxime Breban, and Peter Pietschmann

J Rheumatol. 2009 Jan;36(1):120-6.

PMID: 19040304

113.

Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile

idiopathic arthritis: a bone damage biomarker?

P Spelling, E Bonfa, VF Caparbo, and RM Pereira

Scand J Rheumatol, Nov 2008; 37(6): 439-44.

PMID: 18802807

114.

Bone markers predict cardiovascular events in chronic kidney disease.

A Fahrleitner-Pammer, J Herberth, SR Browning, B Obermayer-Pietsch, G

Wirnsberger, H Holzer, H Dobnig, and HH Malluche

J Bone Miner Res. 2008 Nov;23(11):1850-8.

PMID: 18597636

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 18/29

115.

Modifying RANKL/OPG mRNA Expression in Differentiating and Growing Human

Primary Osteoblasts.

M Giner, M J Montoya, M A Vazquez, M J Rios, R Moruno, M J Miranda, and R

Perez-Cano

Horm Metab Res. 2008 Dec;40(12):869-74.

PMID: 18932123

116.

Bone remodeling biomarkers of periodontal disease in saliva.

BD Frodge, JL Ebersole, RJ Kryscio, MV Thomas, and CS Miller

J Periodontol. 2008 Oct;79(10):1913-9.

PMID: 18834246

117.

Serum osteoprotegerin concentrations are decreased in women with the polycystic

ovary syndrome.

Héctor F Escobar-Morreale, José I Botella-Carretero, Ma Ángeles Martínez-García,

Manuel Luque-Ramírez, Francisco Álvarez-Blasco, and José L San Millán

Eur. J. Endocrinol., Sep 2008; 159: 225 - 232.

PMID: 18579554

118.

Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in

healthy women and men.

K Kerschan-Schindl, J Wendlova, S Kudlacek, A Gleiss, W Woloszczuk, and P

Pietschmann

Exp Clin Endocrinol Diabetes, August 1, 2008; 116(8): 491-5.

PMID: 18072013

119.

α1β1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in

human T cells and enhance their osteoclastogenic function

Gendron S, Boisvert M, Chetoui N, Aoudjit F.

Immunology. 2008;125(3):359-369.

PMCID: PMC2669139

120.

Does Osteoprotegerin or Receptor Activator of Nuclear Factor-κB Ligand Mediate

the Association between Bone and Coronary Artery Calcification?

Bakhireva LN, Laughlin GA, Bettencourt R, Barrett-Connor E.

The Journal of Clinical Endocrinology and Metabolism. 2008;93(5):2009-2012.

PMCID: PMC2386279

121.

The differential expression of osteoprotegerin (OPG) and receptor activator of

nuclear factor κB ligand (RANKL) in human osteoarthritic subchondral bone

osteoblasts is an indicator of the metabolic state of these disease cells

Tat SK, Pelletier J-P, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J.

Clinical and experimental rheumatology. 2008;26(2):295-304.

PMCID: PMC5247261

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 19/29

122.

High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of

receptor activator of nuclear factor-kappaB ligand (RANKL) to OPG correlate with

disease severity in patients with primary knee osteoarthritis.

A Pilichou, I Papassotiriou, K Michalakakou, S Fessatou, E Fandridis, G

Papachristou, and E Terpos

Clin Biochem, Jun 2008; 41(9): 746-9.

PMID: 18355453

123.

OPG and sRANKL serum concentrations in osteopenic, postmenopausal women

after 2-year Genistein administration.

Herbert Marini, Letteria Minutoli, Francesca Polito, Alessandra Bitto, Domenica

Altavilla, Marco Atteritano, Agostino Gaudio, Susanna Mazzaferro, Alessia Frisina,

Nicola Frisina, Carla Lubrano, Michele Bonaiuto, Rosario D’Anna, Maria Letizia

Cannata, Francesco Corrado, Francesco Cancellieri, Marianna Faraci, Rolando

Marini, Elena Bianca Adamo, Steven Wilson, and Francesco Squadrito

JBMR, May 2008, Vol 23, No 5, 715-720

PMID: 18433304

124.

Osteoclast inhibitory effects of vitamin k2 alone or in combination with etidronate

or risedronate in patients with rheumatoid arthritis: 2-year results.

M Morishita, M Nagashima, K Wauke, H Takahashi, and K Takenouchi

J Rheumatol, Mar 2008; 35(3): 407-13.

PMID: 18260178

125.

Risedronate reduces osteoclast precursors and cytokine production in

postmenopausal osteoporotic women.

P D'Amelio, A Grimaldi, S Di Bella, C Tamone, SZ Brianza, MG Ravazzoli, P

Bernabei, MA Cristofaro, GP Pescarmona, and G Isaia

J Bone Miner Res, Mar 2008; 23(3): 373-9.

PMID: 17967134

126.

Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-

B ligand levels in women with established osteoporosis treated with teriparatide.

Athanasios D Anastasilakis, Dimirtios G Goulis, Stergios A Polyzos, Spiridon

Gerou, Vasiliki Pavlidou, George Koukoulis, and Avraam Avramidis

Eur. J. Endocrinol., Mar 2008; 158: 411 - 415.

127.

Does Osteoprotegerin or RANKL Mediate the Association Between Bone and

Coronary Artery Calcification?

Ludmila N. Bakhireva, Gail A. Laughlin, Ricki Bettencourt, and Elizabeth Barrett-

Connor

J. Clin. Endocrinol. Metab., Mar 2008; 10.1210/jc.2007-2624

PMCID: PMC2386279

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 20/29

128.

Effects of compression force on fibroblast growth factor-2 and receptor activator

of nuclear factor kappa B ligand production by periodontal ligament cells in vitro.

R Nakajima, M Yamaguchi, T Kojima, M Takano, and K Kasai

J Periodontal Res, Apr 2008; 43(2): 168-73.

PMID: 18302618

129.

Constitutional Thinness: Unusual Human Phenotype of Low Bone Quality.

Bogdan Galusca, Mohamed Zouch, Natacha Germain, Cecile Bossu, Delphine

Frere, Francois Lang, Marie-Helene Lafage-Proust, Thierry Thomas, Laurence Vico,

and Bruno Estour

J Clin Endocrinol Metab. January 2008, 93(1):110-117

PMID: 17956951

130.

Increased augmentation index and central aortic blood pressure in osteoporotic

postmenopausal women.

RA Mangiafico, C Alagona, P Pennisi, N Parisi, M Mangiafico, F Purrello, and CE

Fiore

Osteoporos Int, Jan 2008; 19(1): 49-56.

PMID: 17676381

131.

Bone mineral apparent density in juvenile dermatomyositis: the role of lean body

mass and glucocorticoid use.

RA Santiago, CA Silva, VF Caparbo, AM Sallum, and RM Pereira

Scand J Rheumatol, Jan 2008; 37(1): 40-7.

PMID: 18189194

132.

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone

mineral density in healthy Chinese women.

HY Zhao, JM Liu, G Ning, YJ Zhao, Y Chen, LH Sun, LZ Zhang, MY Xu, and JL Chen

Osteoporos Int, Feb 2008; 19(2): 221-6.

PMID: 17703270

133.

The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin

Cytokine System in Primary Hyperparathyroidism

Inaam A. Nakchbandi, Robert Lang, Barbara Kinder, and Karl L. Insogna

J. Clin. Endocrinol. Metab., Dec 2007; 10.1210/jc.2007-1645.

PMCID: PMC2266956

134.

NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis

and expression of NFATc1 in mouse arthritis without affecting expression of

RANKL, osteoprotegerin or macrophage colony-stimulating factor

Kubota, T., Hoshino, M., Aoki, K., Ohya, K., Komano, Y., Nanki, T., Nobuyuki M.,

Umezawa, K.

Arthritis Research & Therapy, 9(5), R97.

PMCID: PMC2212584

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 21/29

135.

Serum Osteoprotegerin Concentration with Strontium Ranelate Treatment for

Postmenopausal Osteoporosis: An Open, Prospective Study

Ertorer ME, Bakiner O, Anaforoglu I, Sezgin N, Demirag NG, Tutuncu NB.

Current Therapeutic Research, Clinical and Experimental. 2007;68(4):217-225.

PMCID: PMC3967269

136. The Sex-Specific Association of Serum OPG and RANKL with Bone Mineral Density

in Older Adults: The Rancho Bernardo Study.

Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E.

European journal of endocrinology / European Federation of Endocrine Societies.

2007;156(5):555-562.

PMCID: PMC2642656

137. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by

synovial fluids from patients with a loose joint prosthesis and from osteoarthritis

patients

Andersson MK, Lundberg P, Ohlin A, et al.

Arthritis Research & Therapy. 2007;9(1):R18. doi:10.1186/ar2127.

PMCID: PMC1860076

138.

Bone structure and metabolism in a rodent model of male senile osteoporosis.

P Pietschmann, M Skalicky, M Kneissel, M Rauner, G Hofbauer, D Stupphann, and

A Viidik

Exp Gerontol, Nov 2007; 42(11): 1099-108.

139.

Genetic background influences fluoride's effects on osteoclastogenesis.

D Yan, A Gurumurthy, M Wright, TW Pfeiler, EG Loboa, and ET Everett

Bone, Dec 2007; 41(6): 1036-44.

PMCID: PMC2238641

140.

Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced

bone mineral density in patients with adolescent idiopathic scoliosis.

KT Suh, SS Lee, SH Hwang, SJ Kim, and JS Lee

Eur Spine J, Oct 2007; 16(10): 1563-9.

PMCID: PMC2078303

141.

Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis.

M Mogi and J Otogoto

Arch Oral Biol, Sep 2007; 52(9): 894-8.

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 22/29

142.

Changes of OPG and RANKL concentrations in Crohn's disease after infliximab

therapy.

Pal Miheller, Gyorgyi Müzes, Karoly Racz, Anna Blazovits, Peter Lakatos, Laszlo

Herszenyi, and Zsolt Tulassay

Inflamm Bowel Dis. 2007 Nov;13(11):1379-84.

PMID: 17663430

143.

Soluble Receptor Activator of Nuclear Factor-B Ligand and Risk for Cardiovascular

Disease.

Stefan Kiechl, Georg Schett, Judith Schwaiger, Klaus Seppi, Paula Eder, Georg

Egger, Peter Santer, Agnes Mayr, Qingbo Xu, and Johann Willeit

Circulation, Jul 2007; 116: 385 - 391.

144.

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients

with multiple myeloma. Clinical correlations.

V Goranova-Marinova, S Goranov, P Pavlov, and T Tzvetkova

Haematologica, Jul 2007; 92(7): 1000-1.

PMID: 17606458

145.

Juvenile Paget's disease: the second reported, oldest patient is homozygous for

the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates

circulating immunoreactive osteoprotegerin levels.

MP Whyte, PN Singhellakis, MB Petersen, M Davies, WG Totty, and S Mumm

J Bone Miner Res, Jun 2007; 22(6): 938-46.

PMID: 17352649

146.

Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered

bone metabolism and lower bone mass in hypercholesterolaemic subjects.

RA Mangiafico, G Malaponte, P Pennisi, G Li Volti, G Trovato, M Mangiafico, Y

Bevelacqua, F Mazza, and CE Fiore

J Intern Med, Jun 2007; 261(6): 587-96.

PMID: 17547714

147.

The sex-specific association of serum osteoprotegerin and receptor activator of

nuclear factor B legend with bone mineral density in older adults: the Rancho

Bernardo Study.

Anna Stern, Gail A Laughlin, Jaclyn Bergstrom, and Elizabeth Barrett-Connor

Eur. J. Endocrinol., May 2007; 156: 555 - 562.

PMCID: PMC2642656

148.

Alterations in circulating osteoimmune factors may be responsible for high bone

resorption rate in HIV-infected children and adolescents.

S Mora, I Zamproni, L Cafarelli, V Giacomet, P Erba, G Zuccotti, and A Vigano

AIDS, May 2007; 21(9): 1129-35.

PMID: 17502723

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 23/29

149.

Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic

liver transplantation: relationship with metabolic bone disease.

A Monegal, M Navasa, P Peris, L Alvarez, F Pons, J Rodes, and N Guanabens

Liver Int, May 2007; 27(4): 492-7.

PMID: 17403189

150.

The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.

N Morabito, GT Russo, A Gaudio, A Lasco, A Catalano, E Morini, F Franchina, D

Maisano, M La Rosa, M Plota, A Crifo, A Meo, and N Frisina

Bone, Jun 2007; 40(6): 1588-94.

PMID: 17412659

151.

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis

patients are unable to predict their responses to infliximab.

T. Lequerré, F. Jouen, M. Brazier, S. Clayssens, N. Klemmer, J.-F. Ménard, O.

Mejjad, A. Daragon, F. Tron, X. Le Loët, and O. Vittecoq

Rheumatology, Mar 2007; 46: 446 - 453.

PMID: 16899502

152.

RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated

juvenile dermatomyositis.

Kelly A Rouster-Stevens, Craig B Langman, Heather E Price, Roopa Seshadri,

Richard M Shore, Kathy Abbott, and Lauren M Pachman

Arthritis Rheum, Feb 2007; 56(3): 977-983.

PMID: 17328075

153.

Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in

patients with beta-thalassemia major.

NG Angelopoulos, A Goula, E Katounda, G Rombopoulos, V Kaltzidou, D Kaltsas, S

Malaktari, V Athanasiou, and G Tolis

J Bone Miner Metab, Jan 2007; 25(1): 60-7.

PMID: 17187195

154.

An increased osteoprotegerin serum release characterizes the early onset of

diabetes mellitus and may contribute to endothelial cell dysfunction.

Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C,

Capitani S, Zauli G.

Am J Pathol. 2006 Dec;169(6):2236-44.

PMCID: PMC1762477

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 24/29

155.

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-

kappaB ligand concentrations and normalises indices of bone remodeling in

patients with relapsed multiple myeloma.

Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli

A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.

Br J Haematol. 2006 Dec;135(5):688-92.

PMID: 17107351

156.

IL-7 Up-Regulates TNF-α-Dependent Osteoclastogenesis in Patients Affected by

Solid Tumor

Ilaria Roato, Giacomina Brunetti, Eva Gorassini, Maria Grano, Silvia Colucci, Lisa

Bonello, Lucio Buffoni, Roberto Manfredi, Enrico Ruffini, Davide Ottaviani, Libero

Ciuffreda, Antonio Mussa, and Riccardo Ferracini

PLoS ONE. 2006;1(1):e124.

PMCID: PMC1762428

157.

An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of

Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction

Paola Secchiero, Federica Corallini, Assunta Pandolfi, Agostino Consoli, Riccardo

Candido, Bruno Fabris, Claudio Celeghini, Silvano Capitani, and Giorgio Zauli

The American Journal of Pathology. 2006;169(6):2236-2244.

PMCID: PMC1762477

158.

Association of 12 serum biochemical markers of angiogenesis, tumour invasion

and bone turnover with bone metastases from breast cancer: a crossectional and

longitudinal evaluation

Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P.

British Journal of Cancer. 2006;95(4):506-514.

PMCID: PMC2360666

159.

Serum OPG and RANKL levels before and after intravenous bisphosphonate

treatment in Paget's disease of bone.

Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati, A,

De Paola V, Valleggi F, Nuti R.

Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18.

PMID: 16979395

160.

Increased serum osteoprotegerin values in long-lived subjects: different effects of

inflammation and bone metabolism.

Mazziotti G, Amato G, Sorvillo F, Piscopo M, Rizzo MR, Lalli E, Iride L, Ciuffi M,

Molinari AM, Paolisso G, Carella C.

Eur J Endocrinol. 2006 Mar;154(3):373-7.

PMID: 19346738

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 25/29

161.

Association between phosphate removal and markers of bone turnover in

haemodialysis patients.

Albalate M, de la Piedra C, Fernandez C, Lefort M, Santana H, Hernando P,

Hernandez J, Caramelo C.

Nephrol Dial Transplant. 2006 Jun;21(6):1626-32.

PMID: 16490746

162.

Are activated T cells regulators of bone metabolism in children with Crohn

disease?

FA Sylvester, PM Davis, N Wyzga, JS Hyams, and T Lerer

J Pediatr, Apr 2006; 148(4): 461-6

PMID: 16647405

163.

High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in

Langerhans cell histiocytosis.

Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K,

Tsunematu Y, Fujimoto J, Imashuku S.

Pediatr Blood Cancer. 2006 Aug;47(2):194-9.

PMID: 16358318

164.

Bisphosphonate treatment does not affect serum levels of osteoprotegerin and

RANKL in hypercalcemic cancer patients.

Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC,

Pecherstorfer M.

Anticancer Res. 2005 Sep-Oct;25(5):3607-12.

PMID: 16101188.

165.

Specific biochemical markers of bone metabolism and cytokine study confirm the

diagnosis of malignant infantile osteopetrosis at birth using cord blood sample.

Chan MH, Wong K, Chan IH, Luo YF, Tam S, Lam CW.

Pathology 37:1, 2005, 51 – 55

PMID: 15875734

166.

Low bone density and low serum levels of soluble RANK ligand are associated with

severe arterial calcification in patients with Takayasu arteritis.

Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM.

Rheumatology 2005 44(12):1503-1506

PMID: 16219645

167.

Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and

relationship with BMD assessed in female twins.

Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen

K, Langdahl BL.

Bone 2005 Apr;36(4):727-35

PMID: 15781001

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 26/29

168.

Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and

Experimental Heart Failure.

Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S,

Christensen G, Gullestad L, Aukrust P.

Circulation. 2005;111:2461-2468

PMID: 15883214

169.

The RANKL/OPG system is activated in inflammatory bowel disease and relates to

the state of bone loss.

Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H.

Gut 2005 54: 479-487

PMCID: PMC1774465

170.

Relationships between the changes of serum levels of OPG and RANKL with age,

menopause, bone biochemical markers and bone mineral density in Chinese

women aged 20-75.

Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL.

Calcif Tissue Int 2005 Jan;76(1):1-6

PMID: 15455183.

171.

Changes in osteoprotegerin/RANKL system, bone mineral density, and bone

biochemicals markers in patients with recent spinal cord injury.

Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E,

Ohanna F, Cristol JP, Rossi M, Leroux JL.

Calcif Tissue Int 2005 Jun;76(6):404-11

PMID: 15812577

172.

Osteoprotegerin and RANKL in alcoholic liver cirrhosis.

Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J,

Pons-Romero F.

Liver International 2005 25:2 305

PMID: 15780054

173.

Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL)

concentrations in normal children and in children with pubertal precocity, Turner's

syndrome and rheumatoid arthritis.

Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari

E, Cocchi D

Clin Endocrinol (Oxf). 2004 Jan;60(1):87-91.

PMID: 14678293

174.

Soluble RANKL and Risk of Nontraumatic Fracture.

Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A,

Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J.

JAMA.2004; 291:2703

PMID: 14996780

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 27/29

175.

Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor

RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease

patients

FRANCHIMONT, N., REENAERS, C., LAMBERT, C., BELAICHE, J., BOURS, V.,

MALAISE, M., DELVENNE P., LOUIS, E.

Clinical and Experimental Immunology, 2004 : 138(3), 491–498.

PMCID: PMC1809233

176.

Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of

Coronary Artery Disease in Men.

Schoppet M, Schaefer JR, Hofbauer LC.

Circulation. 2003 Mar 25;107(11):e76;

PMID: 12654623

177.

Serum osteoprotegerin but not receptor activator of NF-{kappa}B ligand

correlates with Larsen score in rheumatoid arthritis.

Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A.

Ann Rheum Dis 2004 63: 216-217

PMCID: PMC1754876

178.

Increased expression of receptor activator of NF-kappaB ligand (RANKL), its

receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's

disease patients.

Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne

P, Louis E.

Clin Exp Immunol 2004 Dec;138(3):491-8

PMCID: PMC1809233

179.

Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in

rheumatoid arthritis: comparison with IL1ß and tumour necrosis factor.

Dai S, Nishioka K, Yudoh K.

Annals of the Rheumatic Diseases 2004;63:1379-1386

PMCID: PMC1754791

180.

Low bone density and abnormal bone turnover in patients with atherosclerosis of

peripheral vessels.

Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE.

Osteoporosis International 2004, 15:5, 389 – 395

PMID: 14661073

181.

Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK

ligand serum levels in healthy young women.

Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M.

Clinical Endocrinology 60:2 2004, p214

PMID: 14725683

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 28/29

182.

T cells support osteoclastogenesis in an in vitro model derived from human

multiple myeloma bone disease: the role of the OPG/TRAIL interaction.

Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R,

Liso A, Capalbo S, Liso V, Zallone A, Grano M.

Blood, 104:12, 2004. 3722-3730

PMID: 15308561

183.

OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis,

osteoarthritis and spondylarthropathy.

Krystufkova O, Niederlova J, Senolt V, Hladikova M, Ruzickova S, Vencovsky J.

Arthritis Res Ther 2003, 5(Suppl 1):102

PMCID: PMC2833669

184.

Receptor Activator of Nuclear Factor kß Ligand (RANKL)/Osteoprotegerin (OPG)

Ratio Is Increased in Severe Osteolysis.

Eva Grimaud, Luc Soubigou, Séverine Couillaud, Patrick Coipeau, Anne Moreau,

Norbert Passuti, François Gouin, Françoise Redini, and Dominique Heymann

American Journal of Pathology, Vol. 163, No. 5, 2003

PMCID: PMC1892410

185.

Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio

predicts survival in multiple myeloma: proposal for a novel prognostic index.

Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N,

Yataganas X, Goldman JM, Rahemtulla A.

Blood. 2003 Aug 1;102(3):1064-9.

PMID: 12689925.

186.

Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in

serum.

Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W.

Clin Lab. 2003;49(9-10):461-3

PMID: 14572201

187.

OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis,

osteoarthritis and spondylarthropathy

Krystufkova O, Niederlova J, Senolt V, Hladikova M, Ruzickova S, Vencovsky J.

Arthritis Research & Therapy. 2003;5(Suppl 1):102.

PMCID: PMC2833669

188.

Unusual Association between Increased Bone Resorption and Presence of

Paroxysmal Nocturnal Hemoglobinuria Phenotype in Multiple Myeloma.

Terpos E, Samarkos M, Meletis C, Apostolidou E, Tsironi M, Korovesis K,

Mavrogianni D, Viniou N, Meletis J.

International Journal of Hematology 78: 4, 2003, 344 - 348

PMID: 14686493

BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA

Last update March 2018

BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 29/29

189.

Effect of Anticoagulants and Storage Temperature on the Stability of Receptor

Activator for Nuclear Factor-B Ligand and Osteoprotegerin in Plasma and Serum.

Evans MJ, Livesey JH, Ellis MJ, Yandle TG.

Clin Chem 2003 49: 2083-2085.

PMID: 11311219

190.

Osteoprotegerin and sRANKL serum levels in multiple myeloma patients.

Barbara Kruk, Maria Kraj, Piotr Centkowski, Urszula Sokołowska

Centr Eur J Immunol 2002 ; 27 (4) : 129-135

191.

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B

ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone

disease.

Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S,

Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V.

Blood 2002 Dec 15;100(13):4615-21

PMID: 12393684